Equities research analysts expect Epizyme Inc (NASDAQ:EPZM) to report sales of $2.15 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Epizyme’s earnings, with the highest sales estimate coming in at $4.20 million and the lowest estimate coming in at $100,000.00. Epizyme reported sales of $10.00 million during the same quarter last year, which would suggest a negative year over year growth rate of 78.5%. The business is expected to issue its next quarterly earnings results on Friday, August 3rd.
On average, analysts expect that Epizyme will report full-year sales of $4.83 million for the current fiscal year, with estimates ranging from $300,000.00 to $10.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $24.55 million per share, with estimates ranging from $300,000.00 to $125.24 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Epizyme.
Epizyme (NASDAQ:EPZM) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.05. During the same period last year, the business posted ($0.56) earnings per share.
A number of analysts have issued reports on EPZM shares. ValuEngine lowered Epizyme from a “sell” rating to a “strong sell” rating in a report on Monday, April 9th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price (down previously from $26.00) on shares of Epizyme in a report on Wednesday, March 14th. BidaskClub raised Epizyme from a “hold” rating to a “buy” rating in a report on Thursday, March 15th. Leerink Swann raised their target price on Epizyme from $22.00 to $24.00 and gave the company an “outperform” rating in a report on Wednesday, March 14th. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $23.00.
Several hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. bought a new stake in shares of Epizyme in the 1st quarter worth approximately $187,000. Alkeon Capital Management LLC bought a new stake in shares of Epizyme in the 1st quarter worth approximately $799,000. Sio Capital Management LLC bought a new stake in shares of Epizyme in the 1st quarter worth approximately $1,293,000. Palo Alto Investors LP lifted its position in shares of Epizyme by 0.5% in the 1st quarter. Palo Alto Investors LP now owns 6,895,075 shares of the biopharmaceutical company’s stock worth $122,388,000 after acquiring an additional 34,232 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Epizyme by 84.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 25,531 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 11,693 shares during the period. Institutional investors own 85.22% of the company’s stock.
EPZM opened at $13.55 on Monday. The company has a market capitalization of $941.56 million, a price-to-earnings ratio of -6.22 and a beta of 2.09. Epizyme has a 12-month low of $11.15 and a 12-month high of $21.40.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.